查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1709454

传染性肠炎治疗市场，按治疗类型、按病原体类型、按给药途径、按配销通路、按最终用户、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Infectious Enteritis Treatment Market, By Treatment Type, By Pathogen Type, By Route of Administration, By Distribution Channel, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 311 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年传染性肠炎治疗市场规模价值 4.9054 亿美元，2025 年至 2032 年的复合年增长率为 7.20%。

传染性肠炎治疗市场-市场动态

食源性疾病盛行率不断上升，导致全球治疗需求增加。

食源性疾病盛行率的上升是传染性肠炎治疗市场的重要动力。受污染的食物和水是细菌、病毒和寄生虫感染的主要来源，导致腹泻和胃肠炎等疾病。根据世界卫生组织 (WHO) 统计，食源性疾病每年影响数百万人，增加了对抗生素、口服补液盐 (ORS) 和益生菌等有效治疗方法的需求。快速的城市化、恶劣的卫生条件以及不安全的食品处理方式导致食源性疾病激增，尤其是在发展中地区。此外，全球旅行和贸易增加了食源性病原体的跨境传播。抗生素抗药性菌株的增加进一步推动了先进疗法和联合治疗的研究。提高人们意识和卫生习惯的公共卫生运动提高了早期诊断率，促进了市场成长。政府和卫生组织增加对轮状病毒免疫等疫苗接种计画的资助也减少了严重的病毒性肠炎病例。总体而言，食源性疾病发生率的不断上升以及相关的健康风险正在推动传染性肠炎治疗市场的扩张。

传染性肠炎治疗市场—关键见解

根据我们的研究分析师的分析，预测期内（2025-2032 年）全球市场预计年复合成长率约为 7.20%

根据治疗类型细分，预计药物将在 2024 年占据最大市场份额

根据病原体类型细分，细菌是 2024 年的主要病原体类型

根据给药途径细分，口服是 2024 年最主要的给药途径

根据配销通路细分，医院药房是 2024 年领先的配销通路

根据最终用户细分，医院是 2024 年领先的最终用户

按地区划分，北美是 2024 年的主要收入来源

传染性肠炎治疗市场-細項分析：

全球传染性肠炎治疗市场根据治疗类型、病原体类型、给药途径、配销通路、最终用户和地区进行细分。

根据治疗类型，市场分为四大类：药物、疗法、疫苗、支持性护理。药物是传染性肠炎治疗市场中最主要的部分，因为它们在控制细菌、病毒和寄生虫感染方面发挥着至关重要的作用。抗生素广泛用于治疗细菌性肠炎，而抗病毒药物和抗寄生虫药物分别用于治疗病毒和寄生虫感染。抗生素抗药性细菌的日益普及进一步推动了对联合疗法和新一代抗生素的需求。口服补液盐（ORS）对于治疗脱水（肠炎的常见併发症）至关重要。无论急性或慢性，药物的可及性和有效性使其成为主要的治疗选择。此外，网路药局和远距医疗服务的兴起也改善了患者获得基本药物的机会。

依病原体类型，市场分为三类：细菌、病毒、寄生虫。细菌类药物在传染性肠炎治疗市场中占据主导地位，这主要是由于沙门氏菌、大肠桿菌和志贺氏菌等病原体引起的食源性疾病的流行率较高。细菌性肠炎是全球住院的主要原因，增加了对抗生素和支持疗法的需求。抗生素抗药性菌株的出现进一步加速了先进治疗方法和联合药物疗法的研究。受污染的食物和水仍然是主要的传播来源，尤其是在发展中地区。此外，与不安全食品操作有关的疫情持续促使人们提高意识并采取预防措施。诊断技术的快速进步进一步巩固了细菌治疗领域的主导地位，从而能够更快地进行治疗干预。

传染性肠炎治疗市场-地理洞察

受高昂的医疗支出和先进的医疗基础设施的推动，北美在传染性肠炎治疗市场占有相当大的份额。由于食源性疾病发生率不断上升，美国在该地区居于首位，美国疾病管制与预防中心 (CDC) 报告称，每年约有 4,800 万例食源性疾病病例。卫生意识的增强以及强有力的疫苗接种计划（如婴儿轮状病毒免疫）促进了市场的成长。由于食物和水源受到污染，加拿大的肠炎病例也在增加，对快速诊断工具和有效治疗的需求也增加。研究和开发活动十分活跃，重点关注新型抗生素和益生菌，以解决抗生素抗药性病原体问题。此外，优惠的报销政策和政府支持公众健康意识的倡议正在推动市场扩张。远距医疗和网路药局的日益增长的趋势正在提高整个地区治疗的可及性。总体而言，北美强大的医疗保健体系、技术进步和预防保健措施正在推动传染性肠炎治疗市场的成长。

美国在北美传染性肠炎治疗市场占据主导地位，这得益于其食源性疾病的高发性和强大的医疗保健基础设施。根据美国疾病管制与预防中心 (CDC) 的数据，每年约有 4,800 万人患有食源性疾病，这导致对抗生素、口服补液盐 (ORS) 和益生菌等治疗方法的需求强劲。该国拥有完善的疫苗接种计划，包括婴儿轮状病毒免疫接种，有助于减少严重的病毒性肠炎病例。快速 PCR 检测等先进的诊断技术正在支援早期发现和有效治疗。此外，抗生素抗药性细菌感染问题日益严重，推动了新疗法和合併药物的研究。政府加强措施和公共卫生运动力度，提倡卫生和安全的食品习惯，进一步支持了市场的成长。远距医疗和网路药局服务的扩展也提高了全国各地治疗的可近性。总体而言，美国市场受到强有力的医疗政策、技术进步以及对传染病的认识不断提高的推动。

传染性肠炎治疗市场-竞争格局：

传染性肠炎治疗市场竞争激烈，全球多家製药公司专注于药物开发、疫苗和支持疗法。葛兰素史克、赛诺菲和默克等主要公司在疫苗生产方面表现突出，尤其是轮状病毒疫苗，对于预防病毒性肠炎至关重要。辉瑞、强生和拜耳等公司在抗生素领域占据主导地位，主要治疗沙门氏菌和大肠桿菌等细菌感染。诺华和艾伯维等公司推动了益生菌疗法的研究，重点是恢復感染后的肠道健康。抗生素抗药性是细菌性肠炎治疗中日益受到关注的问题，市场在开发抗抗生素组合药物方面竞争激烈。合作、合併和收购是公司扩大投资组合和增强分销网络的常见策略。此外，对快速诊断工具的投资正在增加，罗氏和吉利德科学等公司整合了先进技术以实现早期检测。新兴企业正专注于具有成本效益的治疗方法，以满足发展中地区的需求。总体而言，强大的研发管道、技术进步和策略合作正在塑造传染性肠炎治疗市场的竞争态势。

最新动态：

2022 年 11 月，葛兰素史克公司获得 FDA 批准，可以采用新的口服给药施药器方式註射其轮状病毒疫苗 ROTARIX。这项进步简化了医疗保健提供者的准备工作，无需重新配製剂量，提供了更便捷的选择，并增强了葛兰素史克的业务组合。

目录

第一章：传染性肠炎治疗市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 传染性肠炎治疗市场（依治疗类型划分）
    • 传染性肠炎治疗市场（按病原体类型）
    • 传染性肠炎治疗市场依给药途径划分
    • 传染性肠炎治疗市场（依配销通路）
    • 传染性肠炎治疗市场（按最终用户）摘要
    • 传染性肠炎治疗市场（按国家/地区）
    • 传染性肠炎治疗市场（按地区）
  • 竞争洞察

第三章：传染性肠炎治疗主要市场趋势

  • 传染性肠炎治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 传染性肠炎治疗市场限制
    • 市场限制的影响分析
  • 传染性肠炎治疗市场机会
  • 传染性肠炎治疗市场未来趋势

第四章：传染性肠炎治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：传染性肠炎治疗市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：传染性肠炎治疗市场格局

  • 传染性肠炎治疗市占率分析（2024年）
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：传染性肠炎治疗市场－依治疗类型

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 药物
    • 疗法
    • 疫苗
    • 支持治疗

第八章：传染性肠炎治疗市场－依病原体类型

  • 概述
    • 按病原体类型进行细分份额分析
    • 细菌
    • 病毒性的
    • 寄生

第九章：传染性肠炎治疗市场－依给药途径

  • 概述
    • 按给药途径分類的细分市占率分析
    • 口服
    • 静脉注射（IV）
    • 注射剂

第 10 章：传染性肠炎治疗市场 - 按配销通路

  • 概述
    • 按病原体类型进行细分份额分析
    • 医院药房
    • 零售药局
    • 网路药局

第 11 章：传染性肠炎治疗市场 - 按最终用户

  • 概述
    • 按最终用户细分的份额分析
    • 医院
    • 诊所
    • 门诊手术中心（ASC）
    • 零售药局
    • 网路药局

第 12 章：传染性肠炎治疗市场 - 按地区

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美传染性肠炎治疗主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模和预测，按治疗类型
    • 北美市场规模及预测（按病原体类型）
    • 北美市场规模及预测（按给药途径）
    • 北美市场规模及预测（按配销通路）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲传染性肠炎治疗主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（按治疗类型）
    • 欧洲市场规模及预测（按病原体类型）
    • 欧洲市场规模及预测（依管理途径）
    • 欧洲市场规模及预测（按配销通路）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区传染性肠炎治疗主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依治疗类型）
    • 亚太地区市场规模及预测（依病原体类型）
    • 亚太地区市场规模及预测（依管理途径）
    • 亚太地区市场规模及预测（按配销通路）
    • 亚太地区市场规模及预测（依最终用户）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲传染性肠炎治疗主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（按治疗类型）
    • 拉丁美洲市场规模及预测（按病原体类型）
    • 拉丁美洲市场规模及预测（依管理途径）
    • 拉丁美洲市场规模及预测（按配销通路）
    • LATAM 规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲传染性肠炎治疗主要製造商
    • 中东和非洲市场规模及预测（按国家/地区）
    • 中东和非洲市场规模及预测（按治疗类型）
    • 中东和非洲市场规模及预测（按病原体类型）
    • 中东和非洲市场规模及预测（按管理途径）
    • 中东和非洲市场规模及预测（按配销通路）
    • 中东和非洲市场规模及预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 13 章：传染性肠炎治疗产业主要供应商分析

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • GlaxoSmithKline plc
    • Sanofi SA
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Bayer AG
    • Novartis AG
    • AbbVie Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Takeda Pharmaceutical Company Limited
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim International GmbH
    • Cipla Limited
    • Gilead Sciences, Inc.
    • Sun Pharmaceutical Industries Ltd

第 14 章：360 度分析师视角

第 15 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4902

REPORT HIGHLIGHT

Infectious Enteritis Treatment Market size was valued at US$ 490.54 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

The Infectious Enteritis Treatment Market focuses on medications, therapies, and interventions for managing infectious enteritis, an inflammation of the intestines caused by pathogens such as bacteria, viruses, or parasites. This condition leads to symptoms like diarrhea, abdominal pain, nausea, and vomiting. Common causes include rotavirus, norovirus, E. coli, and Salmonella. Treatment options vary based on the infection type and severity, including oral rehydration therapy (ORT), antibiotics, antivirals, and probiotics to restore gut health. Hospitals, clinics, and pharmacies are key providers of these treatments. Increased prevalence of foodborne illnesses and water contamination has fueled market demand. Advancements in rapid diagnostic tools support early detection and timely treatment. Government initiatives promoting awareness and vaccination programs, such as rotavirus immunization, are contributing to market growth. Regions with limited sanitation infrastructure experience a higher burden, driving demand for affordable and accessible treatments. Pharmaceutical companies are actively investing in research to develop targeted therapies and combination drugs to combat resistant pathogens. Overall, the market continues to expand, driven by growing healthcare needs and technological advancements in diagnostics and therapeutics.

Infectious Enteritis Treatment Market- Market Dynamics

Rising prevalence of foodborne illnesses increasing treatment demand globally.

Rising prevalence of foodborne illnesses is a significant driver for the infectious enteritis treatment market. Contaminated food and water are major sources of bacterial, viral, and parasitic infections, leading to conditions such as diarrhea and gastroenteritis. According to the World Health Organization (WHO), foodborne diseases affect millions of people annually, increasing the demand for effective treatments like antibiotics, oral rehydration solutions (ORS), and probiotics. Rapid urbanization, poor sanitation, and unsafe food handling practices contribute to the surge in foodborne illnesses, especially in developing regions. Additionally, global travel and trade have increased the spread of foodborne pathogens across borders. The rise in antibiotic-resistant strains of bacteria has further driven research into advanced therapies and combination treatments. Public health campaigns promoting awareness and hygiene have improved early diagnosis rates, boosting market growth. Increased funding from governments and health organizations for vaccination programs, such as rotavirus immunization, is also reducing severe cases of viral enteritis. Overall, the growing incidence of foodborne illnesses and the associated health risks are driving the expansion of the infectious enteritis treatment market.

Infectious Enteritis Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2025-2032)

Based on Treatment Type segmentation, Medications was predicted to show maximum market share in the year 2024

Based on Pathogen Type segmentation, bacterial was the leading Pathogen Type in 2024

Based on Route of Administration segmentation, Oral was the leading Route of Administration in 2024

Based on Distribution Channel segmentation, Hospital Pharmacies was the leading Distribution Channel in 2024

Based on end-user segmentation, Hospitals was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Infectious Enteritis Treatment Market- Segmentation Analysis:

The Global Infectious Enteritis Treatment Market is segmented on the basis of Treatment Type, Pathogen Type, Route of Administration, Distribution Channel, End User, and Region.

The market is divided into four categories based on Treatment Type: Medications, Therapies, Vaccines, Supportive Care. Medications are the most dominant segment in the infectious enteritis treatment market, driven by their crucial role in managing bacterial, viral, and parasitic infections. Antibiotics are widely prescribed for bacterial enteritis, while antivirals and antiparasitic drugs address viral and parasitic infections, respectively. The growing prevalence of antibiotic-resistant bacteria has further boosted demand for combination therapies and new-generation antibiotics. Oral rehydration solutions (ORS) are essential for managing dehydration, a common complication of enteritis. The accessibility and effectiveness of medications in both acute and chronic cases make them a primary treatment option. Additionally, the rise of online pharmacies and telemedicine services has improved patient access to essential medications.

The market is divided into three categories based on Pathogen Type: Bacterial, Viral, Parasitic. The bacterial segment is the most dominant in the infectious enteritis treatment market, driven by the high prevalence of foodborne illnesses caused by pathogens such as Salmonella, E. coli, and Shigella. Bacterial enteritis is a leading cause of hospitalizations globally, increasing demand for antibiotics and supportive therapies. The rise of antibiotic-resistant strains has further accelerated research into advanced treatments and combination drug therapies. Contaminated food and water remain major transmission sources, especially in developing regions. Additionally, outbreaks linked to unsafe food practices continue to drive awareness and preventive measures. The bacterial segment's dominance is further supported by rapid diagnostic advancements, enabling quicker treatment interventions.

Infectious Enteritis Treatment Market- Geographical Insights

North America holds a significant share of the infectious enteritis treatment market, driven by high healthcare expenditure and advanced medical infrastructure. The United States leads the region due to a rising prevalence of foodborne illnesses, with the Centers for Disease Control and Prevention (CDC) reporting approximately 48 million foodborne illness cases annually. Increased awareness of hygiene and sanitation, along with strong vaccination programs, such as rotavirus immunization for infants, contribute to market growth. Canada is also witnessing a rise in enteritis cases, driven by contaminated food and water sources, increasing demand for rapid diagnostic tools and effective treatments. Research and development activities are robust, focusing on new antibiotics and probiotics to address antibiotic-resistant pathogens. Additionally, favorable reimbursement policies and government initiatives supporting public health awareness are boosting market expansion. The growing trend of telemedicine and online pharmacies is improving accessibility to treatments across the region. Overall, North America's strong healthcare system, technological advancements, and preventive care initiatives are driving growth in the infectious enteritis treatment market.

The United States dominates the infectious enteritis treatment market in North America, driven by a high prevalence of foodborne illnesses and robust healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC), approximately 48 million people suffer from foodborne illnesses annually, contributing to a strong demand for treatments such as antibiotics, oral rehydration solutions (ORS), and probiotics. The country has well-established vaccination programs, including rotavirus immunization for infants, which helps reduce severe cases of viral enteritis. Advanced diagnostic technologies, such as rapid PCR testing, are supporting early detection and effective treatment. Additionally, the growing issue of antibiotic-resistant bacterial infections is driving research into new therapies and combination drugs. Increased government initiatives and public health campaigns to promote hygiene and safe food practices are further supporting market growth. The expansion of telemedicine and online pharmacy services has also improved accessibility to treatments across the country. Overall, the U.S. market is propelled by strong healthcare policies, technological advancements, and increasing awareness about infectious diseases.

Infectious Enteritis Treatment Market- Competitive Landscape:

The infectious enteritis treatment market is highly competitive, with several global pharmaceutical companies focusing on drug development, vaccines, and supportive therapies. Key players like GlaxoSmithKline, Sanofi, and Merck are prominent in vaccine production, particularly for rotavirus, which is crucial in preventing viral enteritis. Companies such as Pfizer, Johnson & Johnson, and Bayer dominate the antibiotic segment, addressing bacterial infections like Salmonella and E. coli. Increasing research into probiotic therapies is driven by companies like Novartis and AbbVie, focusing on restoring gut health post-infection. The market is witnessing intense competition in developing combination drugs to combat antibiotic resistance, a growing concern in bacterial enteritis treatment. Partnerships, mergers, and acquisitions are common strategies as companies aim to expand their portfolios and enhance distribution networks. Additionally, investments in rapid diagnostic tools are increasing, with firms like Roche and Gilead Sciences integrating advanced technologies for early detection. Emerging players are focusing on cost-effective therapies to meet demand in developing regions. Overall, strong R&D pipelines, technological advancements, and strategic collaborations are shaping the competitive dynamics of the infectious enteritis treatment market.

Recent Developments:

In November 2022, GSK plc received FDA approval for a new oral-dosing applicator-only presentation of ROTARIX, its rotavirus vaccine. This advancement simplifies preparation for healthcare providers by removing the need for dose reconstitution, offering a more convenient option and enhancing GSK's business portfolio.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bayer AG
  • Novartis AG
  • AbbVie Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • Gilead Sciences, Inc.
  • Sun Pharmaceutical Industries Ltd

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Medications
  • Therapies
  • Vaccines
  • Supportive Care

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY PATHOGEN TYPE- MARKET ANALYSIS, 2019 - 2032

  • Bacterial
  • Viral
  • Parasitic

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous (IV)
  • Injectable

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Infectious Enteritis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Infectious Enteritis Treatment Market Snippet by Treatment Type
    • 2.1.2. Infectious Enteritis Treatment Market Snippet by Pathogen Type
    • 2.1.3. Infectious Enteritis Treatment Market Snippet by Route of Administration
    • 2.1.4. Infectious Enteritis Treatment Market Snippet by Distribution Channel
    • 2.1.5. Infectious Enteritis Treatment Market Snippet by End User
    • 2.1.6. Infectious Enteritis Treatment Market Snippet by Country
    • 2.1.7. Infectious Enteritis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Infectious Enteritis Treatment Key Market Trends

  • 3.1. Infectious Enteritis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Infectious Enteritis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Infectious Enteritis Treatment Market Opportunities
  • 3.4. Infectious Enteritis Treatment Market Future Trends

4. Infectious Enteritis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Infectious Enteritis Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Infectious Enteritis Treatment Market Landscape

  • 6.1. Infectious Enteritis Treatment Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Infectious Enteritis Treatment Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
    • 7.1.2. Medications
    • 7.1.3. Therapies
    • 7.1.4. Vaccines
    • 7.1.5. Supportive Care

8. Infectious Enteritis Treatment Market - By Pathogen Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Pathogen Type, 2024 & 2032 (%)
    • 8.1.2. Bacterial
    • 8.1.3. Viral
    • 8.1.4. Parasitic

9. Infectious Enteritis Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Intravenous (IV)
    • 9.1.4. Injectable

10. Infectious Enteritis Treatment Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Pathogen Type, 2024 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Infectious Enteritis Treatment Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 11.1.2. Hospitals
    • 11.1.3. Clinics
    • 11.1.4. Ambulatory Surgical Centers (ASCs)
    • 11.1.5. Retail Pharmacies
    • 11.1.6. Online Pharmacies

12. Infectious Enteritis Treatment Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Infectious Enteritis Treatment Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Infectious Enteritis Treatment Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Infectious Enteritis Treatment Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Infectious Enteritis Treatment Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Infectious Enteritis Treatment Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Infectious Enteritis Treatment Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. GlaxoSmithKline plc
    • 13.2.2. Sanofi S.A.
    • 13.2.3. Johnson & Johnson
    • 13.2.4. Merck & Co., Inc.
    • 13.2.5. Pfizer Inc.
    • 13.2.6. Bayer AG
    • 13.2.7. Novartis AG
    • 13.2.8. AbbVie Inc.
    • 13.2.9. Eli Lilly and Company
    • 13.2.10. F. Hoffmann-La Roche Ltd
    • 13.2.11. Takeda Pharmaceutical Company Limited
    • 13.2.12. AstraZeneca plc
    • 13.2.13. Bristol-Myers Squibb Company
    • 13.2.14. Boehringer Ingelheim International GmbH
    • 13.2.15. Cipla Limited
    • 13.2.16. Gilead Sciences, Inc.
    • 13.2.17. Sun Pharmaceutical Industries Ltd

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us